{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '46.', 'Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men', 'with intermediate-risk prostate cancer. Journal of clinical oncology : official journal of the', 'American Society of Clinical Oncology 2011;29:228-34.', '47.', 'Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and', 'immediate confirmatory biopsy in predicting progression during active surveillance for', 'low risk prostate cancer. The Journal of urology 2011;185:477-82.', '48.', 'Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score', '3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.', '49.', 'Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. Journal', 'of the National Comprehensive Cancer Network : JNCCN 2014;12:686-718.', '50.', 'Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation,', 'diagnosis, treatment, and survival in African American men, affected by prostate cancer.', 'Prostate 2011;71:985-97.', '51.', 'Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate', 'and/or earlier transformation to clinically significant prostate cancer in black than in white', 'American men, and influences racial progression and mortality disparity. The Journal of', 'urology 2010;183:1792-6', '52.', 'Sundi D, Ross AE, Humphreys EB, et al. African American men with very low-risk', 'prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should', 'active surveillance still be an option for them? Journal of clinical oncology : official journal', 'of the American Society of Clinical Oncology 2013;31:2991-7.', '53. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer', 'management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet', '2012;379:1103-11.', '54.', 'Cussenot 0, Cornu JN, Drouin SJ, et al. Secondary chemoprevention of localized', 'prostate cancer by short-term androgen deprivation to select indolent tumors suitable for', 'active surveillance: a prospective pilot phase II study. World journal of urology', '2014;32:545-50.', '55.', 'Shukla-Dave A, Hricak H, Akin 0, et al. Preoperative nomograms incorporating', 'magnetic resonance imaging and spectroscopy for prediction of insignificant prostate', 'cancer. BJU international 2012;109:1315-22', '56.', 'Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance', 'imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.', 'BJU international 2007;99:786-93.', '57.', 'Watanabe Y, Terai A, Araki T, et al. Detection and localization of prostate cancer', 'with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort', 'study. J Magn Reson Imaging 2012;35:1414-21.', '58.', 'Turkbey B, Mani H, Aras 0, et al. Correlation of magnetic resonance imaging tumor', 'volume with histopathology. The Journal of urology 2012;188:1157-63.', '59.', 'Rosenkrantz AB, Kim S, Lim RP, et al. Prostate cancer localization using', 'multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System', '(PI-RADS) and Likert scales. Radiology 2013;269:482-92.', '60.', 'Lee DH, Koo KC, Lee SH, et al. Tumor lesion diameter on diffusion weighted', 'magnetic resonance imaging could help predict insignificant prostate cancer in patients', '74', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'eligible for active surveillance: preliminary analysis. The Journal of urology', '2013;190:1213-7.', '61.', 'Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magnetic', 'resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine /', 'Society of Magnetic Resonance in Medicine 1995;33:697-712.', '62.', 'desouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance', 'imaging in prostate cancer: the value of apparent diffusion coefficients for identifying', 'malignant nodules. The British journal of radiology 2007;80:90-5.', '63.', 'Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of', 'prostate cancer. Nature clinical practice Urology 2005;2:596-607.', '64.', 'Barrett T, Gill AB, Kataoka MY, et al. DCE and DW MRI in monitoring response to', 'androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magnetic', 'resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine /', 'Society of Magnetic Resonance in Medicine 2012;67:778-85.', '65.', 'Mullins JK, Bonekamp D, Landis P, et al. Multiparametric magnetic resonance', 'imaging findings in men with low-risk prostate cancer followed using active surveillance.', 'BJU international 2013;111:1037-45', '66.', 'Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is', 'too little? Cancer research 2011;71:629-33.', '67.', 'Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal', 'prostate cancer. The Journal of clinical investigation 2013;123:4918-22.', '68.', 'Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is', 'associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in', 'localized prostate cancer. Clinical cancer research : an official journal of the American', 'Association for Cancer Research 2003;9:1474-9.', '69.', 'Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows', 'association of PTEN deletion with ERG rearrangement during prostate cancer progression.', 'Modern pathology : an official journal of the United States and Canadian Academy of', 'Pathology, Inc 2009;22:1083-93.', '70. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and', 'tumorigenesis. European journal of biochemistry / FEBS 1999;263:605-11.', '71.', 'Goberdhan DC, Wilson C. PTEN: tumour suppressor, multifunctional growth', 'regulator and more. Human molecular genetics 2003;12 Spec No 2:R239-48.', '72. Antonarakis ES, Keizman D, Zhang Z, et al. An immunohistochemical signature', 'comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving', 'adjuvant docetaxel after prostatectomy. Cancer 2012;118:6063-71.', '73.', 'Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated', 'with increased risk of recurrence after prostatectomy for clinically localized prostate', 'cancer. Modern pathology : an official journal of the United States and Canadian Academy', 'of Pathology, Inc 2012;25:1543-9.', '74.', 'Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic', 'validation and prognostic indicator for a high risk surgical cohort of prostate cancer', 'patients. Clinical cancer research : an official journal of the American Association for Cancer', 'Research 2011;17:6563-73.', '75', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}